Rheumnow

Safety of NSAIDs in Inflammatory Bowel Disease  Screen RA ILD Properly  Biologics Improve Sexual Function in axSpA  Catching PsA before it Starts  Multidimensional Pain inventory in Axial SpA  RA: Does upfront TNFi save heartache?  Novel Insights into Sjogren's Disease  New Paradigms in RA Treatment  Biomarkers in Still's and Macrophage Activation Syndrome  "The Power of Gamma Delta T Cell for Autoimmunity"  The Heartbreak of Sarcoidosis 

NSAID Addition Helps the Spine but not the Hips  Durability and Safety of Bimekizumab  Progressive BiTE in SLE 2  Hydroxychloroquine Reduces Autoantibody Levels  When the Back Hurts: uncovering BASDAI drivers in PsA  The Upper Hand in PsA? Not the Dominant One  Airway Disease in GPA  Wired for Success: Vagal Nerve Therapy in RA  GLP-1 in Knee Osteoarthritis  Disparities in Physical Function in SLE 

Putting Steroid Tapering into Practice in SLE  Tocilizumab Beats Methotrexate in GCA  GLP-1 Receptor Agonists in PsA: Mortality and MACE Safety of CAR-T  ILD in Patients with Connective Tissue Disease  SLGT-2 and GLP-1 in RA: More than Weight Loss  PsA Predictors  Ianalumab: Breakthrough Therapy in Sjogren's

Off the Shelf: CAR-T  Combining CAR-T with CAR-Treg All in One  Tapering in SELECT GCA: Steroids are the Problem  Diagnostic Delays in PsA: A Radiographic Perspective  Late-Breaking Trials in axSpA and PsA  New Approaches to Therapy in PsA  PRED-SAFE: Chronic Prednisone Use  PsA and Brain Fog  CAR-T Therapy: Where is it Heading? 

Join RheumNow Faculty Drs. David Liew, Antoni Chan,  Mrinalini Dey, and Jack Cush as they discuss highlights and key takeaways from the Day 2 Recap on Monday, October 27th, at the 2025 ACR Convergence meeting in Chicago.

A Nose for Vasculitis: ENT Manifestations in ANCA-Associated Disease  Tofacitinib in AxSpA in Developing Countries  Specialized Biomarkers in PsA  B Cell Depletion: Check the Lymph Node  GLP-1 and SGLT-2: Treatments Too Good to Ignore?  Nerandomilast for ILD  PsA: Impact of Sex  Cellular Biomarkers of Rheumatoid Arthritis  Using AI and LLMs in Qualitative Data  Belimumab Before or After Immunosuppressant  Do Patients with Rheumatic Diseases 'Weather' the Storm?  AI in Fellow Recruitment: A New Dawn in Medical Education? 

AI Scribes Found their Favorite Doctors  Hospitalization in Stills: Is it "Still" an Infection? Upadacitinib is a Double Edged Vascular Sword in GCA  Rheumatoid Arthritis: Inject the Steroids Catching AxSpA Early: Closing the Diagnostic Gap  Is Low Disease Activity Low Enough?  Early Peripheral SpA: Is it okay to stop treatment sometimes? Difficult to Manage axSpA

STOP RA Cellular & Serologic Predictors Is AI Smarter than a Doctor? Lung Disease in ANCA-associated Vasculitis  Older Adults Underrepresented in RCTs  Next Generation T-Cell Engager: The Future Lupus in Focus: 2025 ACR Treatment Guidelines for SLE  Psoriatic Arthritis Imaging   

Big takeaways, standout moments, and what set the tone for this year’s conference. We break down the key insights, early trends, and conversations shaping Day 1.

Dr. Jack Cush reviews the news and info reports the day before ACR 2025.

DERM on RheumNow PODCAST (October 2025) Skin important Citations and Content curated for dermatologists – addressing Psoriasis, PsA, CLE, vasculitis, HS, other CTD skin disorders. dermatology drugs, biiologics, JAKs - their use, efficacy and side effects. Features Dr. Jack Cush, Editor at RheumNow.com.  SHOW NOTES 1. Skin Biopsies to Predict Scleroderma Outcomes?  2. Fibromyalgia in PsO & PsA is linked to greater treatment complexity and shorter biologic therapy survival. Retro matched 1:4 cohort study 61K PsO& 244K controls. FM prevalence 3.3% (OR 1.45). In PsA w/ FM, req more biologics w/ decr biologic survival (6 vs 10yrs) w/ incr switching (HR 1.82) https://buff.ly/TCc6Kc8 3. Guselkumab FDA Approved for Pediatric Psoriasis and Psoriatic Arthritis  https://rheumnow.com/news/guselkumab-fda-approved-pediatric-psoriasis-and-psoriatic-arthritis    4. Sonelokimab (SLK) is a nanobody that inhibits IL-17 A&F. Phase 2 ARGO trial 207 active PsA pts Rx w/ SLK 120-mg or 60-mg q4wks or PBO or adalimumab. A

Dr. Jack Cush reviews the news and journal reports, discusses pediatric reports, pregnancy data, diet and nutrition and more.

Dr. Jack Cush reviews the news, journal reports and important associations in rheumatology from the past week on RheumNow.com.

Our final webinar in this month's Rheum to Breathe: ILD campaign brings together ILD experts to discuss best practices in diagnosis, screening, and monitoring, covering: tools, labs, and imaging; timing and frequency of screening; ILD screening in RA; and, referral strategies. Panelists: Shane Shapera, MD Elana Bernstein, MD Bryant England, MD Moderator: Jack Cush, MD

Experts Dr. Jeffrey Curtis and Dr. Kevin Winthrop discuss best practices for shared decision-making, how to talk with patients about the risks of poorly controlled RA, and ways to use a new tool for visualizing the long-term safety of a JAKi.

QD clinics on ILD - lessons from the Clinic; brought to during the "Rheum to Breathe" ILD campaign ILD QD Clinic #4 ILD QD Clinics - Worsening Breathlessness in SSc ILD: The Pressure Is On  ILD QD clinics on ILD #1 - Be Careful What you Look For 

Rheum to Breathe Rx Update ILD Treatment and Guidelines Part 4: Rheum + Pulm Collaborations in ILD including The Rheumatologist and Pulmonologist: Different approaches to the same patient (Dr. Paul Dellaripa and Dr Rachel Putman).

Rheum to Breathe Rx Update ILD Treatment and Guidelines Part 3: ILD Assessment and Management including: Biomarkers in ILD (Dr. Elena Joerns), How to Assess ILD in Patients (Dr. Janet Pope) and Management of SSc ILD (Dr. Alicia Hinze)

Rheum to Breathe Rx Update ILD Treatment and Guidelines Part 2: ILD Treatment including: RA-ILD Treatment Update (Dr. Bryant England), Do DMARDS Affect CTD-ILD Outcomes? (Dr. Elizabeth Volkmann), Non-pharmacologic Treatment of ILD (Dr. Jon Giles) and Transplantation: A real option! (Dr. John Joerns)